Literature DB >> 25451349

End-of-life expenditure in the ICU and perceived quality of dying.

Nita Khandelwal1, Ruth A Engelberg2, David C Benkeser3, Norma B Coe4, J Randall Curtis2.   

Abstract

OBJECTIVE: Although end-of-life care in the ICU accounts for a large proportion of health-care costs, few studies have examined the association between costs and satisfaction with care. The objective of this study was to investigate the association of ICU costs with family- and nurse-assessed quality of dying and family satisfaction.
METHODS: This was an observational study surveying families and nurses for patients who died in the ICU or within 30 h of transfer from the ICU. A total of 607 patients from two Seattle hospitals were included in the study. Survey data were linked with administrative records to obtain ICU and hospital costs. Regression analyses assessed the association between costs and outcomes assessing satisfaction with care: nurse- and family-assessed Quality of Death and Dying (QODD-1) and Family Satisfaction in the ICU (FS-ICU).
RESULTS: For family-reported outcomes, patient insurance status was an important modifier of results. For underinsured patients, higher daily ICU costs were significantly associated with higher FS-ICU and QODD-1 (P < .01 and P = .01, respectively); this association was absent for privately insured or Medicare patients (P = .50 and P = .85, QODD-1 and FS-ICU, respectively). However, higher nurse-assessed QODD-1 was significantly associated with lower average daily ICU cost and total hospital cost (P < .01 and P = .05, respectively).
CONCLUSIONS: Family-rated satisfaction with care and quality of dying varied depending on insurance status, with underinsured families rating satisfaction with care and quality of dying higher when average daily ICU costs were higher. However, patients with higher costs were assessed by nurses as having a poorer quality of dying. These findings highlight important differences between family and clinician perspectives and the important role of insurance status.

Entities:  

Mesh:

Year:  2014        PMID: 25451349      PMCID: PMC4251619          DOI: 10.1378/chest.14-0182

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  29 in total

1.  Quality indicators for end-of-life care in vulnerable elders.

Authors:  N S Wenger; K Rosenfeld
Journal:  Ann Intern Med       Date:  2001-10-16       Impact factor: 25.391

2.  A longitudinal study of the effects of age and time to death on hospital costs.

Authors:  Meena Seshamani; Alastair M Gray
Journal:  J Health Econ       Date:  2004-03       Impact factor: 3.883

3.  Racial and ethnic disparities in palliative care.

Authors:  Kimberly S Johnson
Journal:  J Palliat Med       Date:  2013-09-27       Impact factor: 2.947

4.  Systematic implementation of an advance directive program in nursing homes: a randomized controlled trial.

Authors:  D W Molloy; G H Guyatt; R Russo; R Goeree; B J O'Brien; M Bédard; A Willan; J Watson; C Patterson; C Harrison; T Standish; D Strang; P J Darzins; S Smith; S Dubois
Journal:  JAMA       Date:  2000-03-15       Impact factor: 56.272

5.  The distinction between cost and charges.

Authors:  S A Finkler
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

6.  Prevention of ventilator-associated pneumonia: current practice in Canadian intensive care units.

Authors:  Daren K Heyland; Deborah J Cook; Peter M Dodek
Journal:  J Crit Care       Date:  2002-09       Impact factor: 3.425

7.  Family satisfaction with care in the intensive care unit: results of a multiple center study.

Authors:  Daren K Heyland; Graeme M Rocker; Peter M Dodek; Demetrios J Kutsogiannis; Elsie Konopad; Deborah J Cook; Sharon Peters; Joan E Tranmer; Christopher J O'Callaghan
Journal:  Crit Care Med       Date:  2002-07       Impact factor: 7.598

8.  Use of intensive care at the end of life in the United States: an epidemiologic study.

Authors:  Derek C Angus; Amber E Barnato; Walter T Linde-Zwirble; Lisa A Weissfeld; R Scott Watson; Tim Rickert; Gordon D Rubenfeld
Journal:  Crit Care Med       Date:  2004-03       Impact factor: 7.598

9.  Delayed access to health care: risk factors, reasons, and consequences.

Authors:  J S Weissman; R Stern; S L Fielding; A M Epstein
Journal:  Ann Intern Med       Date:  1991-02-15       Impact factor: 25.391

10.  Effect of ethics consultations on nonbeneficial life-sustaining treatments in the intensive care setting: a randomized controlled trial.

Authors:  Lawrence J Schneiderman; Todd Gilmer; Holly D Teetzel; Daniel O Dugan; Jeffrey Blustein; Ronald Cranford; Kathleen B Briggs; Glen I Komatsu; Paula Goodman-Crews; Felicia Cohn; Ernlé W D Young
Journal:  JAMA       Date:  2003-09-03       Impact factor: 56.272

View more
  4 in total

1.  Cost-effectiveness of Direct Antiviral Agents for Hepatitis C Virus Infection and a Combined Intervention of Syringe Access and Medication-assisted Therapy for Opioid Use Disorders in an Injection Drug Use Population.

Authors:  Elizabeth R Stevens; Kimberly A Nucifora; Holly Hagan; Ashly E Jordan; Jennifer Uyei; Bilal Khan; Kirk Dombrowski; Don des Jarlais; R Scott Braithwaite
Journal:  Clin Infect Dis       Date:  2020-06-10       Impact factor: 9.079

Review 2.  Economic implications of end-of-life care in the ICU.

Authors:  Nita Khandelwal; J Randall Curtis
Journal:  Curr Opin Crit Care       Date:  2014-12       Impact factor: 3.687

3.  Evaluation of the Quality of Dying and Death Questionnaire in Kenya.

Authors:  Kenneth Mah; Richard A Powell; Carmine Malfitano; Nancy Gikaara; Lesley Chalklin; Sarah Hales; Anne Rydall; Camilla Zimmermann; Faith N Mwangi-Powell; Gary Rodin
Journal:  J Glob Oncol       Date:  2019-06

4.  Setting ambitious targets for surveillance and treatment rates among patients with hepatitis C related cirrhosis impacts the cost-effectiveness of hepatocellular cancer surveillance and substantially increases life expectancy: A modeling study.

Authors:  Jennifer Uyei; Tamar H Taddei; David E Kaplan; Michael Chapko; Elizabeth R Stevens; R Scott Braithwaite
Journal:  PLoS One       Date:  2019-08-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.